HUP0100349A3 - Pharmaceutical compositions containing antihyperlipidemic statin-lp(a) inhibitor - Google Patents

Pharmaceutical compositions containing antihyperlipidemic statin-lp(a) inhibitor

Info

Publication number
HUP0100349A3
HUP0100349A3 HU0100349A HUP0100349A HUP0100349A3 HU P0100349 A3 HUP0100349 A3 HU P0100349A3 HU 0100349 A HU0100349 A HU 0100349A HU P0100349 A HUP0100349 A HU P0100349A HU P0100349 A3 HUP0100349 A3 HU P0100349A3
Authority
HU
Hungary
Prior art keywords
antihyperlipidemic
statin
inhibitor
pharmaceutical compositions
compositions containing
Prior art date
Application number
HU0100349A
Other languages
English (en)
Hungarian (hu)
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of HUP0100349A2 publication Critical patent/HUP0100349A2/hu
Publication of HUP0100349A3 publication Critical patent/HUP0100349A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HU0100349A 1997-12-12 1998-11-04 Pharmaceutical compositions containing antihyperlipidemic statin-lp(a) inhibitor HUP0100349A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6943297P 1997-12-12 1997-12-12
PCT/US1998/023480 WO1999030706A1 (en) 1997-12-12 1998-11-04 ANTIHYPERLIPIDEMIC STATIN-LP(a) INHIBITOR COMBINATIONS

Publications (2)

Publication Number Publication Date
HUP0100349A2 HUP0100349A2 (hu) 2001-07-30
HUP0100349A3 true HUP0100349A3 (en) 2002-02-28

Family

ID=22088939

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0100349A HUP0100349A3 (en) 1997-12-12 1998-11-04 Pharmaceutical compositions containing antihyperlipidemic statin-lp(a) inhibitor

Country Status (14)

Country Link
EP (1) EP1037623A1 (cg-RX-API-DMAC7.html)
JP (1) JP2003524582A (cg-RX-API-DMAC7.html)
KR (1) KR20010033017A (cg-RX-API-DMAC7.html)
AU (2) AU1306099A (cg-RX-API-DMAC7.html)
BR (1) BR9813539A (cg-RX-API-DMAC7.html)
CA (1) CA2299397A1 (cg-RX-API-DMAC7.html)
HU (1) HUP0100349A3 (cg-RX-API-DMAC7.html)
IL (1) IL134364A0 (cg-RX-API-DMAC7.html)
IS (1) IS5385A (cg-RX-API-DMAC7.html)
NO (1) NO20002965D0 (cg-RX-API-DMAC7.html)
NZ (1) NZ502874A (cg-RX-API-DMAC7.html)
PL (1) PL343851A1 (cg-RX-API-DMAC7.html)
WO (1) WO1999030706A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA9811349B (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4798814B2 (ja) 1997-01-07 2011-10-19 アミリン・ファーマシューティカルズ,インコーポレイテッド 食物摂取低減用のエキセンジンおよびそのアゴニストの使用
EP1076091A1 (en) * 1999-08-09 2001-02-14 Universite Catholique De Louvain Medicament for the prevention and/or the treatment of ischemic heart and peripheral vascular diseases, tumour and wounds
WO2001051078A1 (en) * 2000-01-10 2001-07-19 Amylin Pharmaceuticals, Inc. Use of exendins and agonists thereof for modulation of triglyceride levels and treatment of dyslipidemia
US20030018040A1 (en) * 2000-02-10 2003-01-23 Yasuo Sugiyama Tnf-alpha inhibitors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2016467A1 (en) * 1989-06-05 1990-12-05 Martin Eisman Method for treating peripheral atherosclerotic disease employing an hmg coa reductase inhibitor and/or a squalene synthetase inhibitor
AU3473193A (en) * 1992-01-17 1993-08-03 Procter & Gamble Company, The Treatment for atherosclerosis
CA2129732A1 (en) * 1992-02-25 1993-09-02 Alain Martin Cytoprotective compositions containing pyruvate and antioxidants
US5720963A (en) * 1994-08-26 1998-02-24 Mary Kay Inc. Barrier disruption treatments for structurally deteriorated skin
US5648387A (en) * 1995-03-24 1997-07-15 Warner-Lambert Company Carboxyalkylethers, formulations, and treatment of vascular diseases
EP0738510A3 (fr) * 1995-04-20 2005-12-21 L'oreal Utilisation d'un inhibiteur d'HMG-coenzyme A-reductase pour lutter contre le vieillissement de la peau et pour traiter l'acné. Composition comprenant au moins un inhibiteur HMG-coenzyme A reductase et au moins un actif possédant des propriétes desquamantes
JP2000508659A (ja) * 1996-04-17 2000-07-11 メルク エンド カンパニー インコーポレーテッド 心血管疾患関連の危険性を低減する組み合わせ療法
NZ503982A (en) * 1997-12-12 2002-03-28 Warner Lambert Co Statin-carboxyalkylether combinations useful for treating vascular disorders and diabetes mellitus

Also Published As

Publication number Publication date
BR9813539A (pt) 2000-10-10
PL343851A1 (en) 2001-09-10
AU1306099A (en) 1999-07-05
IS5385A (is) 2000-02-25
EP1037623A1 (en) 2000-09-27
NZ502874A (en) 2004-03-26
CA2299397A1 (en) 1999-06-24
NO20002965L (no) 2000-06-09
NO20002965D0 (no) 2000-06-09
KR20010033017A (ko) 2001-04-25
IL134364A0 (en) 2001-04-30
ZA9811349B (en) 1999-06-14
HUP0100349A2 (hu) 2001-07-30
WO1999030706A1 (en) 1999-06-24
AU2003244047A1 (en) 2003-09-25
JP2003524582A (ja) 2003-08-19

Similar Documents

Publication Publication Date Title
IL193245A0 (en) Pharmaceutical compositions containing an a?? fragment
PL331531A1 (en) Pharmaceutical aerosol compositions
HUP0001013A3 (en) Oil-free pharmaceutical compositions containing cyclosporin a
GB9727053D0 (en) Pharmaceutical compositions
GB9702238D0 (en) Compositions
HUT74746A (en) Pharmaceutical compositions containing p antagonist
IL112639A0 (en) A pharmaceutical composition containing pravastin
PL334568A1 (en) Paroxetin containing compositions
IL133928A0 (en) Pharmaceutical composition containing peptichemio
IL131917A (en) Pharmaceutical compositions containing lamivudine
IL131995A0 (en) Gastric-retained pharmaceutical compositions
GB9723985D0 (en) Pharmaceutical compositions
HUP0004669A3 (en) Pharmaceutical compositions
IL134651A0 (en) Pharmaceutical compositions containing an anti-androgen
HU9700632D0 (en) Pharmaceutical compositions
IL128107A0 (en) Pharmaceutical compositions containing a pkc inhibitor
GB9723948D0 (en) Decontamination compositions
IL134364A0 (en) ANTIHYPERLIPIDEMIC STATIN-LP (a) INHIBITOR COMBINATIONS
ZA982117B (en) Pharmaceutical compositions
HUP0003528A3 (en) Pharmaceutical compositions containing dihydropolyprenols
GB9703109D0 (en) Compositions
GB2285923B (en) Pharmaceutical compositions containing N-acetal-cysteine
HU9701093D0 (en) Pharmaceutical composition containing huminic acid
GB9718270D0 (en) Pharmaceutical compositions
PL330972A1 (en) Tetrahydrolypstatin containing compositions